PANCHSHEEL ORGANICS LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 69 | 103 | 105 | 107 | 107 |
| EBITDA (ex other income) | 13 | 20 | 19 | 18 | 14 |
| margin % | 18.6 | 19.4 | 18.0 | 16.4 | 12.7 |
| Owners' profit | 8 | 14 | 14 | 14 | 11 |
| EPS, as reported (₹) | 8.33 | 12.78 | 11.88 | 20.94 | 8.22 |
| ROE % · ROCE % | 17.6 · 22.7 | 14.6 · 19.8 | 11.3 · 15.2 | 10.3 · 13.3 | 7.7 · 10.1 |
| Debt / equity (x) | 0.09 | 0.06 | 0.05 | 0.04 | 0.04 |
| Cash from operations | (2) | 0 | 10 | 4 | 10 |
| Capex | (2) | 0 | (10) | (16) | (7) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 27 | 26 | 28 | 24 | 25 | 27 | 31 |
| Profit before tax | 5 | 5 | 5 | 4 | 4 | 3 | 4 | 3 |
| Net profit | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 2 |
| EPS (₹) | 2.60 | 5.76 | 5.58 | 4.82 | 4.32 | 3.96 | 2.79 | 1.29 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Notice of 37th AGM published in newspapers | compliance | minimal | — | — |
| 8 Sept 2026 · AGM on 30 Sep via video conference; Record Date 23 Sep for Final Dividend | corporate actions | high | — | — |
| 8 Sept 2026 · 37th AGM notice on Sep 30, 2026; final dividend Re 0.80 per share proposed | board shareholder meetings | low | — | — |
| 8 Sept 2026 · 37th AGM scheduled for September 30, 2026 with proposed Rs 0.80 dividend | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Board approves 37th AGM notice and fixes book closure | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Annual Report FY26 filed with 8 percent dividend and leadership changes | results | medium | — | — |
| 31 Aug 2026 · Board meeting on 8 Sep 2026 to consider AGM, dividend and other items | board shareholder meetings | low | — | — |
| 17 Aug 2026 · Newspaper publication of Q1 June 2026 unaudited results | compliance | minimal | — | — |
| 14 Aug 2026 · Panchsheel Organics appoints Chandan Turakhia as director | management changes | medium | — | — |
| 14 Aug 2026 · Promoter elevated to Managing Director at Panchsheel Organics | management changes | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 8.8 | 28.9 | 22 of 169 | 88% |
| P/B | 1.0 | 3.3 | 21 of 163 | 88% |
| ROCE | 9.9 | 10.8 | 98 of 183 | 47% |
| ROE | 7.7 | 10.4 | 104 of 171 | 39% |
| Debt / Equity | 0.0 | 0.1 | 66 of 171 | 62% |
| EBITDA margin | 11.9 | 17.5 | 109 of 165 | 34% |
| Revenue growth | 9.5 | 16.3 | 95 of 161 | 41% |
| Profit growth | (46.3) | 30.9 | 131 of 158 | 17% |
| Market cap | 144 | 839 | 126 of 182 | 31% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
